{
    "Overall_score": {
        "Correlation": 8,
        "Sentiment": 6,
        "Importance": 7,
        "Impact": 7,
        "Duration": 5,
        "Virality": 4,
        "Source_Score": 9,
        "Specificity": 8,
        "Sector_Spread": 8,
        "Tech_Mentions": 2
    },
    "Each_item": [
        {
            "News_content": "Valeant, Mylan, and Actavis eye Pfizer's brand-new generics unit for buyout: Reuters #pharma $PFE $VRX $MYL $ACT",
            "Correlation": 9,
            "Sentiment": 6,
            "Importance": 7,
            "Impact": 7,
            "Duration": 5,
            "Virality": 4,
            "Source_Score": 9,
            "Specificity": 8,
            "Sector_Spread": 7,
            "Tech_Mentions": 1
        },
        {
            "News_content": "Two Broad Morning Views $DDD $PFE $QQQ $SPY $STUDY",
            "Correlation": 3,
            "Sentiment": 5,
            "Importance": 4,
            "Impact": 4,
            "Duration": 3,
            "Virality": 2,
            "Source_Score": 6,
            "Specificity": 3,
            "Sector_Spread": 5,
            "Tech_Mentions": 2
        },
        {
            "News_content": "Pfizerâ€™s new generics unit already has suitors, Reuters reports: Valeant, Actavis and Mylan $PFE $ACT $VRX $MYL",
            "Correlation": 9,
            "Sentiment": 6,
            "Importance": 7,
            "Impact": 7,
            "Duration": 5,
            "Virality": 4,
            "Source_Score": 9,
            "Specificity": 8,
            "Sector_Spread": 8,
            "Tech_Mentions": 1
        }
    ]
}